Nelarabine is a pro-drug of Ara-G.
- TRADE NAMES: Arranon (GSK); Atriance
- INDICATIONS: T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma
- CLASS: Antimetabolite, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Purine analog
- HALF-LIFE: 0.5–3 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Pentostatin
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of Nelarabine in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/28/2025
